PregLem
PregLem is a Geneva biotech, part of Gedeon Richter, whose ulipristal acetate (Esmya) for uterine fibroids went through phase 3 trials it led; it is listed among industry sponsors of cancer-tagged trials.
Overview
PregLem SA, founded in Geneva in 2006 and later acquired by the Hungarian group Gedeon Richter, developed ulipristal acetate (Esmya) for the treatment of uterine fibroids, a benign gynaecological tumour. Its phase 3 programme is registered on ClinicalTrials.gov, where the trials fall under the cancer and neoplasm categories that OnCo's sponsor list draws on.
Similar pages
not linked directly; found by shared links- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyIntra-IMMUSG
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyLee's Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyNobelpharma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyR-Pharm
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.